中国P站

Bariatric surgery; Appetite regulation; Gut hormones; Ghrelin; GLP-1; Satiety; Weight loss; Gut-brain axis; Roux-en-Y Gastric Bypass; Sleeve Gastrectomy

Introduction

Bariatric surgery profoundly reconfigures the human body's approach to appetite, leading to substantial and lasting weight loss. A core mechanism involves significant alterations in key appetite hormones, such as ghrelin, often referred to as the "hunger hormone," and Glucagon-Like Peptide-1 (GLP-1), which promotes fullness and satiety [1].

These changes in hormonal balance together actively reduce hunger sensations and enhance feelings of satiety after meals [1].

In essence, these hormonal shifts are fundamental drivers for the observed weight reduction, acting as a powerful mechanism far beyond simple caloric restriction alone [1].

Importantly, these surgical interventions induce lasting changes not only in the regulation of appetite hormones but also within the composition and function of the gut microbiota [2].

Both of these factors contribute collectively to sustained weight loss and overall improvements in metabolic health over the long term [2].

Understanding these complex, long-term interactions between hormones, gut microbes, and their collective impact is crucial for grasping the enduring benefits of such surgical procedures [2].

Roux-en-Y Gastric Bypass (RYGB), for instance, represents a specific type of bariatric surgery that fundamentally changes how appetite is controlled [3].

It achieves this through a sophisticated combination of altered gut hormone secretion patterns, modified neural signaling pathways between the gut and the brain, and even shifts in an individual's taste preferences [3].

These combined mechanisms work in concert to effectively reduce food intake and improve glycemic control significantly in the period following the procedure [3].

When various surgical approaches are compared, such as Sleeve Gastrectomy (SG) versus RYGB, we observe distinct patterns in how appetite and satiety hormones respond and change [4].

These differences directly influence patients' subjective reports of hunger and fullness, highlighting individualized responses to surgery [4].

Recognizing these specific variations is extremely helpful in tailoring surgical choices to meet the unique needs and expectations of individual patients concerning their long-term appetite control [4].

Beyond the purely physiological signals governing energy balance, bariatric surgery also significantly affects the brain's reward system [5].

This effect leads to a noticeable reduction in the preference for high-calorie, often highly palatable, foods [5].

This dual impact, addressing both homeostatic eating (driven by the body's energy needs) and hedonic eating (driven by pleasure and reward), is a critical factor driving significant and sustained weight loss in patients [5].

Interestingly, there's a parallel to be drawn: both bariatric surgery and Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RA), a class of medications, modulate appetite and food preferences through mechanisms that, while similar, also possess distinct characteristics [6].

This observation suggests intriguing possibilities for potential synergies when combining therapies or for exploring alternative therapeutic avenues for weight management by targeting these common pathways of satiety and reward [6].

The surgical intervention profoundly reorganizes the enteroendocrine system, leading to a dramatic alteration in the secretion of gut hormones [7].

This creates an internal environment that actively promotes feelings of satiety and significantly diminishes sensations of hunger [7].

These intricate changes in the gut hormone landscape are absolutely fundamental to achieving the sustained weight loss and the comprehensive metabolic improvements consistently observed after bariatric surgery [7].

More specifically, gastric bypass surgery dramatically alters the profile of gut hormones; it notably increases the release of anorexigenic peptides, which are responsible for suppressing appetite, while simultaneously decreasing orexigenic ones, which typically stimulate hunger [8].

This hormonal rebalancing is incredibly effective at suppressing appetite, thereby contributing significantly to the procedure's success in managing severe obesity [8].

It's important to underscore that while both Sleeve Gastrectomy and gastric bypass induce beneficial changes in appetite hormones, their specific impacts are not identical in all aspects [9].

There are discernible differences, particularly in the magnitudes of ghrelin suppression and the elevation of GLP-1 levels [9].

These differential hormonal effects contribute directly to the distinct clinical outcomes and varied patient experiences associated with each specific surgical type [9].

Ultimately, a key outcome of bariatric surgery is its fundamental reconfiguration of the gut-brain axis [10].

This intricate communication network between the digestive system and the central nervous system is modified to enhance satiety signals and reduce hunger signals transmitted to the brain [10].

This complex physiological adaptation following the surgical intervention is absolutely key to achieving sustained appetite control and long-term weight loss [10].

Description

Bariatric surgery represents a powerful intervention for obesity management, primarily by inducing profound changes in appetite regulation. One of the most significant impacts involves altering the secretion and action of key appetite hormones. For instance, ghrelin, often termed the "hunger hormone," is typically suppressed, while hormones like Glucagon-Like Peptide-1 (GLP-1), known for promoting satiety, are significantly elevated [1]. This rebalancing acts synergistically to reduce hunger sensations and increase feelings of fullness, which is a major contributor to the substantial weight loss observed post-surgery, moving beyond simple caloric restriction [1]. Furthermore, the long-term effects of bariatric surgery extend to lasting alterations in not just appetite hormones but also the gut microbiota, both of which are critical for sustained weight loss and improved metabolic health [2].

Specific surgical procedures, such as Roux-en-Y Gastric Bypass (RYGB), achieve these effects through multifaceted mechanisms. RYGB fundamentally reworks appetite control by altering gut hormone secretion, modifying neural signaling pathways, and even influencing taste preferences [3]. These combined actions lead to a noticeable reduction in food intake and improved glycemic control, which are vital for managing obesity-related comorbidities [3]. When comparing different surgical types, like Sleeve Gastrectomy (SG) and RYGB, it becomes clear that their impacts on appetite and satiety hormones are not identical [4]. These distinct hormonal profiles lead to varying patient experiences regarding hunger and fullness, suggesting that surgical choice can be tailored to individual patient needs and expectations concerning appetite control [4].

The influence of bariatric surgery goes beyond the physiological regulation of energy balance; it also impacts the brain's reward system [5]. This leads to a decreased preference for high-calorie, palatable foods, demonstrating a dual effect on both homeostatic and hedonic eating behaviors [5]. This comprehensive modulation of eating drives significant and sustained weight loss. Interestingly, these effects show parallels with pharmacological interventions; both bariatric surgery and Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RA) modulate appetite and food preferences through similar, though distinct, pathways [6]. This offers insights into potential synergistic treatments or alternative therapeutic avenues for weight management by targeting shared mechanisms of satiety and food reward [6].

The intricate changes in the enteroendocrine system are fundamental to the success of bariatric surgery. The procedure profoundly reorganizes gut hormone secretion, fostering an internal environment that strongly favors satiety and effectively reduces hunger [7]. These deep-seated changes are indispensable for the sustained weight loss and the metabolic improvements observed in patients [7]. Specifically, gastric bypass surgery is known to dramatically shift the balance of gut hormones, increasing anorexigenic (appetite-suppressing) peptides while decreasing orexigenic (appetite-stimulating) ones [8]. This hormonal rebalancing acts as a potent mechanism for suppressing appetite, playing a crucial role in the procedure's efficacy against severe obesity [8].

Despite their shared goal, Sleeve Gastrectomy and gastric bypass induce differential changes in appetite hormones [9]. For example, the extent of ghrelin suppression and GLP-1 elevation can vary between the two procedures [9]. These differences in hormonal modulation are key to understanding the distinct clinical outcomes and patient experiences associated with each surgical type [9]. Ultimately, a critical component of bariatric surgery's efficacy lies in its fundamental reconfiguration of the gut-brain axis [10]. This complex communication network is recalibrated to enhance satiety signals and diminish hunger signals transmitted from the gut to the brain, which is essential for sustained appetite control and long-term weight loss as a physiological adaptation to the intervention [10].

Conclusion

Bariatric surgery dramatically alters appetite regulation, leading to substantial and sustained weight loss by impacting multiple physiological pathways. It significantly changes the balance of appetite hormones, such as reducing ghrelin (hunger hormone) and increasing GLP-1 (satiety hormone), thereby decreasing hunger and enhancing fullness [1]. These hormonal shifts are key drivers for weight loss, going beyond simple caloric restriction [1]. The surgery also induces lasting changes in both appetite-regulating hormones and the gut microbiota, which are crucial for sustained weight loss and improved metabolic health [2]. Specific procedures like Roux-en-Y Gastric Bypass (RYGB) modify appetite through altered gut hormone secretion, neural signaling, and taste preferences, leading to reduced food intake and improved glycemic control [3]. Comparing Sleeve Gastrectomy (SG) and RYGB reveals distinct patterns in appetite and satiety hormone changes, influencing patient-reported hunger and fullness and guiding surgical choice [4]. Beyond hormones, bariatric surgery affects the brain's reward system, reducing preference for high-calorie foods, impacting both homeostatic and hedonic eating [5]. This shows parallels with GLP-1 receptor agonists, suggesting common therapeutic pathways [6]. The reorganization of gut hormone secretion profoundly favors satiety and reduces hunger, with gastric bypass notably increasing anorexigenic and decreasing orexigenic peptides [7, 8]. While both SG and gastric bypass are effective, their specific impacts on hormones like ghrelin and GLP-1 differ, contributing to varied clinical outcomes [9]. Ultimately, bariatric surgery reconfigures the gut-brain axis, strengthening satiety and diminishing hunger signals for sustained appetite control and weight loss [10].

References

1. Ahmed E, Mostafa A, Islam G (2021) .Obes Surg 31:3824-3837.

   , ,

2. Min-Jie G, Wei H, Jia-Hui C (2023) .Obes Surg 33:2542-2559.

   , ,

3. Sini HN, Satu TKP, Sanna LL (2020) .J Clin Endocrinol Metab 105:e2259-e2268.

   , ,

4. Mariana V, João A, Joana GN (2022) .Obes Rev 23:e13426.

   , ,

5. Nanna DMJ, Rasmus KJ, Signe SS (2023) .Surg Obes Relat Dis 19:585-592.

   , ,

6. Caroline MA, Daniel GK, Robert K (2023) .Curr Obes Rep 12:440-456.

   , ,

7. Stephanie CFELB, Charlotte CWD, Judith GMAvD (2024) .J Clin Med 13:91.

   , ,

8. Ilias NG, Panagiotis KM, Efstratios NG (2021) .World J Gastroenterol 27:7062-7076.

   , ,

9. Marcio SCS, Lucas VTS, Priscila PAM (2021) .Obes Surg 31:5462-5473.

   , ,

10. Marianna IPP, Anastasios GA, Konstantinos GM (2022) .J Clin Med 11:6109.

    , ,